Hemab Therapeutics Holdings, Inc. (COAG)Healthcare | Biotechnology | Cambridge, United States | NasdaqGS
29.80 USD
-0.59
(-1.941%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
After hours: 29.80 |
Hot Take ↕ | Oct. 10, 2026, 2:36 a.m. EDT
The immediate outlook is bearish due to a sharp technical breakdown; the stock has lost nearly 20% over the last two weeks, dropping from highs near $38 to lows around $28, signaling strong selling pressure despite the recent IPO debut. While the business fundamentals are actually quite robust—boasting a fortress balance sheet with massive cash reserves relative to debt and a pristine current ratio—the lack of any price history since the IPO prevents a meaningful assessment of long-term market validation, capping the long-term rating at neutral. Furthermore, there is no dividend income to offset the capital risk. The disconnect between the pristine balance sheet and the volatile, downward-sloping price action suggests the market is currently pricing in significant clinical or commercial uncertainty that outweighs the company's financial strength in the short term. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.117959 |
| AutoARIMA | 0.119580 |
| AutoETS | 0.119581 |
| AutoTheta | 0.267628 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 5.14 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.173 |
| Excess Kurtosis | -0.16 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.226 |
| Market Cap | 1,392,020,992 |
| Forward P/E | -11.74 |
| Website | https://www.hemab.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.106176496 |
| Address1 | 101 Main Street |
| Address2 | Suite 1220 |
| All Time High | 55.42 |
| All Time Low | 23.0 |
| Ask | 37.95 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 468,810 |
| Average Daily Volume3 Month | 462,987 |
| Average Volume | 462,987 |
| Average Volume10Days | 468,810 |
| Bid | 21.6 |
| Bid Size | 2 |
| Book Value | 9.726 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 29.8 |
| Current Ratio | 35.847 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 31.0475 |
| Day Low | 29.11 |
| Debt To Equity | 0.226 |
| Display Name | Hemab Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp | 1,786,451,400 |
| Earnings Timestamp End | 1,794,832,200 |
| Earnings Timestamp Start | 1,794,832,200 |
| Ebitda | -86,893,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -10.767 |
| Enterprise Value | 935,587,072 |
| Eps Current Year | -3.1 |
| Eps Forward | -2.5375 |
| Eps Trailing Twelve Months | -4.33 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 42.4108 |
| Fifty Day Average Change | -12.610802 |
| Fifty Day Average Change Percent | -0.29734883 |
| Fifty Two Week Change Percent | -10.617649 |
| Fifty Two Week High | 55.42 |
| Fifty Two Week High Change | -25.619999 |
| Fifty Two Week High Change Percent | -0.462288 |
| Fifty Two Week Low | 23.0 |
| Fifty Two Week Low Change | 6.799999 |
| Fifty Two Week Low Change Percent | 0.29565215 |
| Fifty Two Week Range | 23.0 - 55.42 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,777,642,200,000 |
| Float Shares | 20,311,830 |
| Forward Eps | -2.5375 |
| Forward P E | -11.743842 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 59 |
| Fullday Change | -0.59000015 |
| Fullday Change Percent | -1.9414287 |
| Fullday Price | 29.8 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.1078 |
| Held Percent Institutions | 0.92430997 |
| Implied Shares Outstanding | 46,712,117 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,026-05-01 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts. |
| Long Name | Hemab Therapeutics Holdings, Inc. |
| Market | us_market |
| Market Cap | 1,392,020,992 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_1994300807 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -83,235,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,715,736,057 |
| Number Of Analyst Opinions | 5 |
| Open | 30.59 |
| Operating Cashflow | -77,330,000 |
| Operating Margins | 0.0 |
| Phone | (617) 553-3952 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 29.8 |
| Post Market Time | 1,791,921,677 |
| Previous Close | 30.39 |
| Price Eps Current Year | -9.612904 |
| Price Hint | 2 |
| Price To Book | 3.0639522 |
| Profit Margins | 0.0 |
| Quick Ratio | 35.482 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.59 |
| Regular Market Change Percent | -1.94143 |
| Regular Market Day High | 31.0475 |
| Regular Market Day Low | 29.11 |
| Regular Market Day Range | 29.11 - 31.0475 |
| Regular Market Open | 30.59 |
| Regular Market Previous Close | 30.39 |
| Regular Market Price | 29.8 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 441,950 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 46,712,117 |
| Shares Percent Shares Out | 0.0726 |
| Shares Short | 3,390,130 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 2,107,998 |
| Short Name | Hemab Therapeutics Holdings, In |
| Short Ratio | 5.66 |
| Source Interval | 15 |
| State | MA |
| Symbol | COAG |
| Target High Price | 65.0 |
| Target Low Price | 58.0 |
| Target Mean Price | 61.2 |
| Target Median Price | 60.0 |
| Total Cash | 457,460,000 |
| Total Cash Per Share | 9.793 |
| Total Debt | 1,026,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.33 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 37.02053 |
| Two Hundred Day Average Change | -7.2205315 |
| Two Hundred Day Average Change Percent | -0.19504127 |
| Type Disp | Equity |
| Volume | 441,950 |
| Website | https://www.hemab.com |
| Zip | 2,142 |